These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 11911284)

  • 1. Tissue distribution and plasma pharmacokinetics of UCN-01 at steady-state and following bolus administration in rats: influence of human alpha1-acid glycoprotein binding.
    Hedaya MA; Daoud SS
    Anticancer Res; 2001; 21(6A):4005-10. PubMed ID: 11911284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans.
    Fuse E; Tanii H; Takai K; Asanome K; Kurata N; Kobayashi H; Kuwabara T; Kobayashi S; Sugiyama Y
    Cancer Res; 1999 Mar; 59(5):1054-60. PubMed ID: 10070963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiological modeling of altered pharmacokinetics of a novel anticancer drug, UCN-01 (7-hydroxystaurosporine), caused by slow dissociation of UCN-01 from human alpha1-acid glycoprotein.
    Fuse E; Hashimoto A; Sato N; Tanii H; Kuwabara T; Kobayashi S; Sugiyama Y
    Pharm Res; 2000 May; 17(5):553-64. PubMed ID: 10888307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01.
    Kurata N; Kuwabara T; Tanii H; Fuse E; Akiyama T; Akinaga S; Kobayashi H; Yamaguchi K; Kobayashi S
    Cancer Chemother Pharmacol; 1999; 44(1):12-8. PubMed ID: 10367744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.
    Fuse E; Tanii H; Kurata N; Kobayashi H; Shimada Y; Tamura T; Sasaki Y; Tanigawara Y; Lush RD; Headlee D; Figg WD; Arbuck SG; Senderowicz AM; Sausville EA; Akinaga S; Kuwabara T; Kobayashi S
    Cancer Res; 1998 Aug; 58(15):3248-53. PubMed ID: 9699650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing the impact of binding of UCN-01 to human alpha1-acid glycoprotein by encapsulation in liposomes.
    Yamauchi M; Kusano H; Nakakura M; Kato Y
    Biol Pharm Bull; 2005 Jul; 28(7):1259-64. PubMed ID: 15997110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine.
    Sparreboom A; Chen H; Acharya MR; Senderowicz AM; Messmann RA; Kuwabara T; Venzon DJ; Murgo AJ; Headlee D; Sausville EA; Figg WD
    Clin Cancer Res; 2004 Oct; 10(20):6840-6. PubMed ID: 15501960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled release of a protein kinase inhibitor UCN-01 from liposomes influenced by the particle size.
    Yamauchi M; Kusano H; Saito E; Abe M; Tsutsumi K; Uosaki Y; Nakakura M; Kato Y; Aoki N
    Int J Pharm; 2008 Mar; 351(1-2):250-8. PubMed ID: 17904317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tryptophan residues play an important role in the extraordinarily high affinity binding interaction of UCN-01 to human alpha-1-acid glycoprotein.
    Katsuki M; Chuang VT; Nishi K; Suenaga A; Otagiri M
    Pharm Res; 2004 Sep; 21(9):1648-55. PubMed ID: 15497692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of photoaffinity labeling and site-directed mutagenesis for identification of the key residue responsible for extraordinarily high affinity binding of UCN-01 in human alpha1-acid glycoprotein.
    Katsuki M; Chuang VT; Nishi K; Kawahara K; Nakayama H; Yamaotsu N; Hirono S; Otagiri M
    J Biol Chem; 2005 Jan; 280(2):1384-91. PubMed ID: 15509559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
    Sausville EA; Arbuck SG; Messmann R; Headlee D; Bauer KS; Lush RM; Murgo A; Figg WD; Lahusen T; Jaken S; Jing X; Roberge M; Fuse E; Kuwabara T; Senderowicz AM
    J Clin Oncol; 2001 Apr; 19(8):2319-33. PubMed ID: 11304786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850).
    Perez RP; Lewis LD; Beelen AP; Olszanski AJ; Johnston N; Rhodes CH; Beaulieu B; Ernstoff MS; Eastman A
    Clin Cancer Res; 2006 Dec; 12(23):7079-85. PubMed ID: 17145831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide.
    Cárcel-Trullols J; Torres-Molina F; Araico A; Saadeddin A; Peris JE
    Cancer Chemother Pharmacol; 2004 Aug; 54(2):153-60. PubMed ID: 15114410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration.
    Rivière GJ; Gentry WB; Owens SM
    J Pharmacol Exp Ther; 2000 Mar; 292(3):1042-7. PubMed ID: 10688621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs.
    Kobayashi S; Sakai T; Dalrymple PD; Wood SG; Chasseaud LF
    Arzneimittelforschung; 1993 Dec; 43(12):1367-77. PubMed ID: 8141830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoreactivity and pharmacokinetics of horse anti-scorpion venom F(ab')2-scorpion venom interactions.
    Pépin-Covatta S; Lutsch C; Grandgeorge M; Lang J; Scherrmann JM
    Toxicol Appl Pharmacol; 1996 Nov; 141(1):272-7. PubMed ID: 8917700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
    Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of plasma protein binding displacement on the pharmacokinetics, tissue and tumor concentrations and efficacy of brequinar, a highly protein-bound antitumor agent.
    Aungst BJ; Blake JA; Rogers NJ; Dusak BA
    J Pharmacol Exp Ther; 1990 Apr; 253(1):230-6. PubMed ID: 2329509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of different dosing schedules of UCN-01 on its pharmacokinetics and cardiohaemodynamics in dogs.
    Kurata N; Imabeppu S; Nitoh M; Kobayashi H; Kuwabara T; Kobayashi S
    J Pharm Pharmacol; 2000 Nov; 52(11):1327-35. PubMed ID: 11186240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased elimination of unbound prazosin in the presence of alpha 1-acid glycoprotein in the rat in vivo.
    Oie S; Fiori F; Chiang J
    J Pharmacol Exp Ther; 1987 Jun; 241(3):934-8. PubMed ID: 3598910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.